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A better understanding of the mechanisms employed by HIV-1 to escape immune 
responses still represents one of the major tasks required for the development of novel 
therapeutic approaches targeting a disease still lacking a definitive cure. Host innate 
immune responses against HIV-1 are key in the early phases of the infection as they 
could prevent the development and the establishment of two hallmarks of the infection: 
chronic inflammation and viral reservoirs. Sialic acid-binding immunoglobulin-like lectins 
(Siglecs) belong to a family of transmembrane proteins able to dampen host immune 
responses and set appropriate immune activation thresholds upon ligation with their 
natural ligands, the sialylated carbohydrates. This immune-modulatory function is also 
targeted by many pathogens that have evolved to express sialic acids on their surface 
in order to escape host immune responses. HIV-1 envelope glycoprotein 120 (gp120) 
is extensively covered by carbohydrates playing active roles in life cycle of the virus. 
Indeed, besides forming a protecting shield from antibody recognition, this coat of 
N-linked glycans interferes with the folding of viral glycoproteins and enhances virus 
infectivity. In particular, the sialic acid residues present on gp120 can bind Siglec-7 on 
natural killer and monocytes/macrophages and Siglec-1 on monocytes/macrophages 
and dendritic cells. The interactions between these two members of the Siglec family 
and the sialylated glycans present on HIV-1 envelope either induce or increase HIV-1 
entry in conventional and unconventional target cells, thus contributing to viral dissem-
ination and disease progression. In this review, we address the impact of Siglecs in the 
pathogenesis of HIV-1 infection and discuss how they could be employed as clinic and 
therapeutic targets.
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iNTRODUCTiON
Immunoglobulin-like receptors constitutively present on cellular surface play a key role in the immune 
recognition of both cell targets and pathogens due to their high plasticity that makes them easily 
adaptable to adopt an infinite range of molecular structures. In this regard, glycans expressed by sev-
eral microbes are recognized by several immunoglobulin type-I lectins, including sialic acid-binding 
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immunoglobulin-like lectins (Siglecs). Siglecs belong to a fam-
ily of transmembrane proteins that display a variable numbers 
of C2-set immunoglobulin domains (from 1 in CD33 to 16 in 
Siglec-1), an amino-terminal V-set immunoglobulin domain that 
recognizes sialic acid residues (1–3) and a conserved arginine 
residue that binds carbohydrates. Fifteen different functional 
Siglecs have been identified in humans, including Siglec-12 that 
has lost the ability to bind sialic acids. They can be classified in 
two main subgroups: the first one comprises the evolutionary 
conserved Siglecs-1, -2, -4, and -15 that differ from the second 
cluster of rapidly evolving Siglecs. This latter type-I lectin sub-
group includes Siglec-3, -5 to -11, -14, and -16 sharing structural 
similarities with the first identified CD33/Siglec-3 (4–6). Siglecs 
are constitutively expressed mostly on cells derived from the 
hematopoietic lineage and belonging to innate immunity, such 
as monocytes/macrophages, neutrophils, basophils, eosinophils, 
dendritic cells (DCs), and natural killer (NK) cells (5). In con-
trast, adaptive immune cells such as T  lymphocytes have very 
low or undetectable surface levels of these type-I lectins (7). Of 
note, the expression of distinct member of Siglec family can be 
either restricted to specific immune cells (i.e., Siglec-1 and -11 
constitutively present only on macrophages) (5, 8, 9) or shared by 
several myeloid and lymphoid populations (i.e., Siglec-7 and -9 
expressed on NK cells, monocytes and macrophages or Siglec-5 
on monocytes, B cells, and neutrophils) (5, 10–12).
In regard to Siglec binding to their putative ligands, each one of 
these lectin-type molecules has a preferential specificity for sialic 
acid residues, and the recognition depends on both glycan struc-
tures and glycan modifications associated with sulfation, acetyla-
tion, and glycosylation reactions (13, 14). Sialic acids comprise a 
family of more than 50 carbohydrates that share a nine-carbon 
backbone (C1-9) representing the terminal unit of glycoproteins 
and glycolipids (gangliosides) phylogenetic conserved among 
different species including humans (15). Siglec-binding sites 
are usually masked at the cellular surface due to cis interactions 
with highly expressed low affinity sialic acids. Their unmasking 
in response to cellular activation or sialidase treatment cleaves 
the cis low affinity ligands and allows free interactions in trans 
with highly glycosylated ligands. Nonetheless, trans interactions 
can also occur when Siglecs encounter other cells or pathogens 
expressing higher affinity ligands competing with cis (16, 17). 
Following the binding with these sugars, Siglecs regulate and 
control inflammatory responses by setting appropriate thresh-
olds of immune activation (5, 18–20). Indeed, Siglec cytosolic 
tails mostly include immune-receptor tyrosine-based inhibi-
tory motifs (ITIMs) or ITIM-like domains, whose engagement 
inhibits leukocyte proliferation, induces apoptosis, modulates 
endocytosis and the production of inflammatory cytokines.
In the context of host–pathogen interactions, sialic acids and 
their glycan residues expressed on the envelopes of several patho-
gens serve as recognition molecules interacting with lectin-type 
molecules such as Siglecs. This is one of the established mecha-
nisms of viral entry in immune cells, as demonstrate with highly 
pathogenic A, B, and C strains of influenza that encode hemagglu-
tinin enriched with sialic acid residues (21, 22). The engagement 
of Siglecs in response to their recognition of microbial glycan 
residues has been first described as a mechanism to dampen host 
immune responses following the encounter with inflammatory 
stimuli (23–26). Later on, it became evident that pathogens took 
advantage of the Siglec recognition by evolving and expressing 
sialic acids on their surface in order to escape host inflammatory 
responses (20, 27). More recently, a novel and emerging working 
hypothesis postulates that CD33-related Siglecs also evolved in 
response to pathogen manipulation by associating their intra-
cellular domains with either immune-receptor tyrosine-based 
activation motifs (ITAM) or unconventional activating from of 
ITIMs in Siglec-7 (17, 20, 28–30).
Several lines of evidence indicate that also HIV-1 employs 
sialic acid associated-mechanisms to facilitate its viral entry in 
target cells. Indeed, HIV-1 envelope (env) is equipped with an 
N-terminal glycoprotein 120 (gp120) heavily conjugated with 
sialic acids residues that, besides forming a protecting shield 
from antibody (Ab) recognition, also enhance virus infectivity 
and dissemination by binding sugar-binding receptors expressed 
on host immune cells (31–39). Indeed, several human lectin-type 
receptors including galectins (40, 41), defensins (42–44), and 
others (45–51) have been shown to bind HIV-1 env by recogniz-
ing glycans expressed on gp120. The identification and charac-
terization of these sialic acid-binding receptors also explain the 
different susceptibility to HIV-1 to infect cells expressing different 
repertoires of Siglecs (52). Although these lectin-type receptors 
were identified in the early 1980s, only recently their interactions 
with HIV-1 have been disclosed. In particular, Siglec-1 (53–55) 
and Siglec-7 (52, 56) have been reported to bind HIV-1 envelope, 
thus inducing and/or facilitating HIV-1 infection and disease 
progression. This review provides an updated summary in regard 
the pathogenic role of Siglecs and also discusses how they could 
be employed as clinic and therapeutic targets.
KiNeTiCS OF SiGLeCS DURiNG THe 
COURSe OF Hiv-1 iNFeCTiON
Human NK  cells are known as effector-cells capable of killing 
potentially dangerous non-self targets (i.e., viral-infected, tumor-
transformed, or allogeneic cells) and produce pro-inflammatory 
cytokines such as interferon-γ (IFN-γ) upon activation and in 
the absence of a prior sensitization to specific antigens. NK cell 
recognition of autologous cell targets is mediated by a large fam-
ily of inhibitory NK cell receptors (iNKRs) including killer cell 
immunoglobulin-like receptors and C-type lectins that recognize 
different alleles of major histocompatibility complex of class I 
(MHC-I) (i.e., missing-self hypothesis). Decreased expression or 
absence of self-MHC-I on viral-infected or tumor-transformed 
or allogeneic cells trigger NK  cell effector functions via the 
engagement of large family of activating NKRs (aNKRs) that 
bind their putative ligands expressed on cellular targets (57–59). 
Even though the inhibitory signals are considered dominant over 
the activating ones, the dynamic balance between iNKRs and 
aNKRs is key for the regulation of NK-cell-mediated clearance 
of viruses and tumors (60–62). NK  cells are CD3neg/CD19neg/
CD14neg lymphocytes whose phenotype is defined by the expres-
sion of CD56 and CD16 (56, 59). In healthy subjects, the largest 
subset of circulating NK cells (up to 90%) is CD56dim/CD16pos, 
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has a high cytolytic potential, and can also produce high levels 
of pro-inflammatory and antiviral cytokines upon stimulation. 
The second circulating subset of immune-regulatory CD56bright/
CD16dim-neg NK cells (up to 10–15%) is able to secrete high amount 
of pro-inflammatory cytokines while displaying poor cytotoxicity 
(59, 63, 64).
The first studies assessing the frequencies and the functions 
of NK cells in HIV-1 infected patients with high levels of ongo-
ing viral replication reported an overall decrease of both their 
percentage and absolute number in the peripheral blood. Either 
apoptosis or cellular migration to peripheral tissues has been pro-
posed as possible mechanisms driving the depletion of circulating 
NK cells during the course of HIV-1 infection (65, 66). Only later, 
it became evident that HIV-1 viremia does not reduce the abso-
lute number of circulating NK cells but rather induce a pathologic 
redistribution of their subsets since from the early stages of the 
infection. Indeed, others and we identified and characterized 
an anergic population of CD56neg/CD16pos (CD56neg) NK  cells 
expanded in viremic patients and counterbalancing the reduction 
of the CD56dim/CD16pos cytolytic NK cell subset. An early deple-
tion of the immune-regulatory CD56bright/CD16neg NK cells has 
been also described (64, 67–69). This subset of CD56neg NK cells 
in HIV-1 infection is characterized by an imbalanced repertoire 
of NKRs associated with a remarkably impaired cytotoxic activity 
and secretion of antiviral cytokines/chemokines (68, 70). These 
pathological features explain, at least in part, the impairments 
of CD56neg NK cells in the clearance of both tumor-transformed 
and viral-infected cell targets as well as their defective interac-
tions with autologous DCs (71–73). The mechanisms driving the 
expansion of this pathologic CD56neg NK cells during the course 
of HIV-1 infection remain unknown, although several lines of 
evidence indicate that this phenomenon is not HIV-1 specific. 
Indeed, high frequencies of CD56neg NK cells have been reported 
in other viral infections [such as human cytomegalovirus or 
hepatitis C virus (HCV)] and autoimmune diseases (such as 
myasthenia gravis or dermatomyositis) (64). Hence, it is conceiv-
able to hypothesize that persistent inflammation characterizing 
several human chronic immunological diseases might be one of 
the factors inducing the expansion of CD56neg NK cells.
The down-modulation of CD56 is not the only NK surface 
marker whose surface level is altered by high levels of ongoing 
HIV-1 replication. In fact, also the expressions as well as the 
functional relevance of several aNKRS and iNKRs are affected 
by HIV-1 viremia (62, 74). Indeed, these markedly dysfunctional 
CD56neg NK cell subsets express high levels of iNKRS and low lev-
els of aNKRs, a phenomenon that contributes, at least in part, to a 
defective control of HIV-1 replication and to disease progression 
(64, 72). The HIV-1-induced pathologic modulation of CD56 and 
NKR surface expression does not occur during the acute phase 
of the infection but require a chronic exposure of NK  cells to 
chronic viral replication (75). In contrast, the down-modulation 
of Siglec-7, a iNKRs constitutively expressed on the majority of 
NK  cells, is detectable since from the earliest phases of HIV-1 
infection and precedes the phenotypic changes of CD56 and 
NKRs on NK cells (56). This phenomenon makes it possible to 
identify two distinct subsets present in different stages of HIV-1 
infection: the Siglec-7neg/CD56dim NK population only present in 
the early phases of HIV-1 infection and the Siglec-7neg/CD56neg 
NK cell subset that become detectable several months later when 
the disease enters in its chronic phase. All these HIV-1-induced 
phenotypic changes are reversible following the administration 
of a successful antiretroviral therapy (ART) and the restoration 
of Siglec-7 expression on NK cells is much faster compared to 
that of CD56, aNKRs, and iNKRs. The impact of viral replication 
in inducing these phenotypic abnormalities is also confirmed 
by the experimental evidence showing that NK cells from those 
HIV-1-infected patients with a low/undetectable levels of viral 
replication that do not progress to AIDS (i.e., long-term non-
progressors or LTNP) are similar and undistinguishable from the 
ones of uninfected healthy individuals (56). Although Siglec-7 is 
an iNKRs containing ITIM-like domains in its cytosolic tail, it has 
been also reported that Siglec-7pos NK cells are more function-
ally relevant compared to their Siglec-7neg counterparts. Indeed, 
the expression of Siglec-7 in NK cells is associated with higher 
levels of aNKRs (i.e., CD16, NKp30, NKp46) and lower levels of 
iNKRs (i.e., CD94/NKG2A, CD158b) (76). This likely explains 
the fact that NK cells still retain a certain degree of antiviral and 
antitumor functions in the acute phases of HIV-1 infection, while 
become anergic and highly dysfunctional only in the chronic 
stages of the disease featuring the expansion of the Siglec-7neg/
CD56neg NK cells (56).
A soluble form of Siglec-7 (sSiglec-7) resulted to be increased 
in the sera of HIV-1-infected patients and could serve as an 
additional clinical biomarker to monitor disease progression. In 
fact, higher serum levels of sSiglec-7 directly correlate with HIV-1 
viremia and parallel the expansion of Siglec-7neg NK cells in HIV-
1-infected patients, thus suggesting that the continuous exposure 
to ongoing viral replication induce the shedding of Siglec-7 recep-
tor from NK  cell surface (52, 56). Among circulating immune 
cells constitutively expressing this C-lectin-type molecule (i.e., 
NK cells and monocytes) (5), the main source of sSiglec-7 seems 
to be NK  cells because a subset of Siglec-7neg monocytes has 
never been reported during the course of HIV-1 infection (52). 
Similarly, it has been recently shown that also the stimulation 
in vitro of NK cells with HCV induces both a significant release 
of sSiglec-7 in culture supernatant and a decrease of Siglec-7 
expression from NK cell surface (77). Further investigations are 
required to identify the cellular and molecular mechanisms that 
certain viruses employ to induce a shedding of this C lectin-type 
receptor selectively on NK cells during the acute phases of the 
infection.
Siglec-1 is a sialoadhesin (i.e., an adhesion molecule present 
on cell surface and binding sialic acid residues) constitutively 
expressed on monocytes and macrophages whose expression is 
remarkably increased on HIV-1 infected monocytes (54, 78, 79). 
These higher amount of Siglec-1 on CD14pos cells are induced by 
IFN-α and IFN-γ, occur rapidly after infection, enhance their 
susceptibility to infection, and are maintained during the follow-
ing chronic phases of HIV-1 disease. In particular, the expression 
of Siglec-1 on monocytes appears to be higher in AIDS patients 
compared to that of asymptomatic HIV-1-infected individuals 
and correlates with plasma viral load. These findings suggest that 
high frequencies of Siglec-1pos/CD14pos monocytes are associated 
with disease progression (80). In addition, higher surface levels 
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of Siglec-1 on monocytes correlate with immune activation as 
the treatment of these cells with IFNs or bacterial compounds 
such as lipopolysaccharide increases the surface amount of this 
type-I lectin. This is consistent with the condition of chronic 
inflammation and immune activation induced by the presence 
of HIV-1 viremia that also triggers the expansion of a subset of 
CD14pos/CD16pos-activated monocytes (54, 78, 81–84). Hence, 
although having different kinetics during the course of HIV-1 
infection, both the expressions of Siglec-1 and Siglec-7 are greatly 
influenced by viral replication and can be used as clinical tools 
to identify and monitor acute and chronic clinical stages of the 
infection.
SiGLeCS iN THe PATHOGeNeSiS OF 
Hiv-1 iNFeCTiON
In addition to CD4pos T  lymphocytes that represent the main 
cell target of HIV-1 infection, the virus is able to also infect 
immune cells of myeloid origin such as DCs and tissue-resident 
macrophages (71, 85). These two latter antigen-presenting cells 
express both CD4 and the chemokine co-receptors CCR5 and 
CXCR4, which are required for a productive HIV-1 infection 
(86). In particular, different Siglecs have been reported to play 
key roles in both binding the virus and facilitating its viral entry 
in monocytes and macrophages due to the fact that HIV-1 env-
gp120 is extensively covered by carbohydrates first processed 
in the endoplasmic reticulum and then further modified in the 
trans-Golgi apparatus (31–35). The high degree of sialylation on 
HIV-1 envelope, other than representing a protecting shield that 
hamper Ab recognition of viral antigens, is also highly permissive 
and facilitates HIV-1 infection of target cells (33, 87–89). Indeed, 
given the high avidity and affinity of Siglecs for sialic acid residues, 
the viral env-gp120 (in particular within the V1/V2 domain) 
represents an important Siglec-binding site (90). Different from 
CD4pos T cells though, monocytes and macrophage are resistant 
to HIV-1-mediated cytopathic effects as there is no depletion of 
these cells either in peripheral blood or tissues of HIV-1-infected 
patients. Moreover, macrophage can serve as cellular storage of 
accumulating virions in their sub-cellular regions that are termed 
“virion containing compartment” and whose origin is still unclear 
(91, 92). The identification of VVCs gave rise among the scientific 
community to the “Trojan horse” metaphor meaning that the 
virus can be hidden in infected macrophages that, in turn, can 
disseminate infectious particles when interplaying with CD4pos 
T cells and/or in response to environmental signals (i.e., cytokines 
or damage-associated molecular patterns). Several experimental 
evidence confirmed the existence of this “Trojan horse” in in vitro 
infected monocytes/macrophages, in the brain of AIDS patients 
with HIV encephalitis (93, 94) as well as in macaques infected 
with Simian immunodeficiency virus (SIV) (95, 96). It is still being 
debated whether HIV-1 infection of macrophages leads to the 
establishment of an additional reservoirs of latently infected cells 
contributing to boost viral replication and disease progression in 
patients undergoing ART interruption (97). In supports to this 
hypothesis, it has been reported that the functional polarization 
of monocyte-derived macrophages (MDM) into M1 cells upon 
exposure to pro-inflammatory signals (i.e., IFN-γ and TNF-α) 
leads to a state of quasi-latency upon HIV-1 infection (98). 
Moreover, recent evidence demonstrates that M2 macrophages 
are more permissive to HIV-infection/replication compared to 
their M1 counterparts. This is associated with the fact that the 
stimulation with macrophage colony-stimulating factor induces 
both in vitro and in vivo the expression on macrophage of several 
cellular receptors required for viral entry, including CD4, CCR5, 
and Siglec-1 (90, 99).
The first evidence of a direct contribution of Siglecs to HIV-1 
pathogenesis has been reported in monocytes with the Siglec-1-
mediated uptake of HIV-1 in a sialic acid-dependent mechanism 
(54). Indeed, Siglec-1 can bind HIV-1 and promote a trans-infec-
tion of monocytes. Unlike the other Siglecs in which the sialic acid 
binding sites could be masked by ligands expressed in cis, Siglec-1 
is equipped with a larger extracellular domain that allow both 
cell-to-cell and cell-to-virus interactions. The discovery of this 
mechanism made it possible to understand that Siglec-1 is able to 
directly interact with HIV-1 and contributes to the spreading of 
HIV-1 infection (5). Moreover, Siglec-1 on macrophages can also 
function as an adhesion molecule carrying sialic acid conjugates 
to T cells (100, 101). Hence, the main current working hypothesis 
postulates that monocytes and macrophages interplay at the same 
time with viral envelope and target cells via Siglec-1 that bridges 
HIV-1 in close proximity to CD4 and chemokine co-receptors 
(Figure  1). This interaction would overcome the electrostatic 
repulsive forces created by the negative charges present on both 
virus envelope and cell surface, thereby unmasking the receptors 
involved in the internalization of HIV-1 and promoting viral 
entry. In support of this hypothesis, several studies showed that 
removal of sialic acids from cell surface or viral envelope with 
neuraminidase treatment increases the susceptibility of target 
cells to be infected and form cellular syncytia (33, 39, 102, 103). 
Moreover, a recent report demonstrated in an in  vivo rodent 
model of HIV infection that the virus can disseminate over long 
distance in a cell-free manner in the blood and lymph and can 
be captured by Siglec-1pos macrophages mainly located at the 
interface between lymphoid tissues and fluids, thus allowing and 
facilitating the trans-infection of lymphocytes (104).
Siglec-1 also mediates HIV-1 trans-infection of mature DCs 
(mDCs) and contributes to viral dissemination via the establish-
ment of immunological synapses between mDCs and T  cells 
in the early steps of the infection at mucosal sites (53). In this 
regard, intra-vaginal inoculation of SIV recruit plasmacytoid 
DCs to lymphoid tissue and increases tissue levels of IFN-α. In 
turn, this pro-inflammatory cytokine induces the maturation of 
DCs and their ability to mediate HIV-1 trans-infection of CD4pos 
T cells and of themselves via Siglec-1 (105, 106). The interactions 
between Siglec-1 expressed on mDCs and sialic acids residues 
present on viral membrane or exosomes also represents a host 
immune mechanism employed by mDCs to process and present 
antigens to CD4pos T cells. HIV-1 evolved to take advantage of this 
physiologic pathway and used mDCs as a carrier of infection (53). 
Recently, it has been proposed that HIV-1 particles do not only 
parasite mDCs in their cellular compartments, but virions are 
also retained on surface-connected plasma membrane invagina-
tions (107) (Figure 1).
A B
FiGURe 1 | Siglecs in the pathogenesis and clinical outcomes of Hiv-1 infection. (A) Chronic HIV-1 infection leads to the downregulation of Siglec-7 
expression on natural killer (NK) cells and increases plasma levels of its soluble form of Siglec-7 (sSiglec-7). (B) Moreover, HIV-1 monocytes/macrophages induces 
higher expressions of Siglec-1, CD4, and chemokine co-receptors (CCR5 and CXCR4) on monocytes and macrophages, while do not affects the constitutive high 
surface levels of Siglec-7 on the same cells. Siglec-1 is also expressed on mature dendritic cells (mDCs), monocytes, and macrophages, and high levels of HIV-1 
viremia increase even more its surface expression on the latter two cell types. Due to their distribution on immune cells and to their ability to bind the viral envelope 
glycoprotein 120 heavily conjugated with sialic acids residues, Siglec-7 and Siglec-1 are highly relevant in the pathogenesis of HIV-1 infection. Indeed, after the 
binding of HIV-1 to Siglec-1, both mDCs and monocytes/macrophages retain virions with different mechanisms, a phenomenon enhancing the HIV-1 infection of 
CD4pos lymphocytes. Moreover, the HIV-1 uptake by Siglec-1 and Siglec-7 further contribute to the spreading of infection by using both DCs and monocyte/
macrophages as cellular-infected carriers of the virus. The shedding of Siglec-7 from NK cells in the presence of high levels of HIV-1 viremia also significantly 
increases HIV-1 viral entry in Siglec-7neg/CD4pos T cells. Finally, the engagement of Siglec-7 on monocytes and macrophages promotes cellular activation in 
monocytes and macrophages and contributes to the establishment of persistent inflammation in HIV-1-infected patients. These abnormalities in Siglec phenotype 
and functions in HIV-1 infection can be used as clinical tools to monitor disease progression or can be targeted to develop innovative therapeutic approaches to limit 
viral spreading and disease progression.
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Monocyte-derived macrophages express different Siglecs that, 
other than binding HIV-1, have been also reported to enhance 
the susceptibility of MDMs to be infected by the same virus (52, 
55). Siglec-1 leads this process by serving as the most effective 
MDM surface receptor up-taking HIV-1 envelope, even though 
its degree of expression on these cells is significantly lower 
compared to that of Siglec-3 and -9. As previously mentioned, 
this is likely due to the fact that Siglec-1 has a larger size with 17 
immunoglobulin domains size and is present in an un-masked 
state, while Siglec-3 and -9 are masked on MDM cell surface and 
display a great affinity toward gp120 only after neuraminidase 
treatment (55). It has been recently reported that also Siglec-7 
acts as a membrane-bound molecule that contributes to enhance 
HIV-1 infection of MDMs (52). Several studies showed that both 
monocytes and macrophages constitutively express high levels of 
Siglec-7 (5, 10, 20, 24, 25, 52), while only one report claiming a 
very low expression of this type-I molecule on MDMs (53). Similar 
to Siglec-1, Siglec-7 binds gp120 present on viral envelope and 
increases the viral entry of HIV-1 in MDMs. Indeed, the masking 
of Siglec-7 greatly reduce the amount of HIV-RNA in MDMs, 
thus decreasing their susceptibility to infection (52) (Figure 1).
Siglec-7 has been recently reported of being able to increase 
the susceptibility to HIV-1 infection even its soluble form (52). 
Indeed, Siglec-7-Fc fusion protein significantly increases HIV-1 
viral entry in Siglec-7neg/CD4pos T  cells. This phenomenon is 
highly relevant in the course of active and chronic HIV-1 infec-
tion since AIDS patients show increased serum levels of sSiglec-7. 
Again, although a direct experimental evidence is still lacking, 
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it has been hypothesized that sSiglec-7 is shed from the cellular 
surface on NK cells since high levels of HIV-1 replication induce 
an early decrement of Siglec-7 specifically on this population and 
not on in monocytes/macrophages and CD8pos T cells, which are 
the other two immune cells constitutively expressing this type-I 
lectin (10, 52, 56). Even though the mechanisms, the kinetic, and 
the pathogenic relevance of the sSiglec-7-mediated infection of 
CD4pos T cells are still unknown, it is conceivable to hypothesize 
that this c-lectin-type molecule could serve as a highly efficient 
and T-trophic carrier of the virus in the bloodstream and tissue 
sites (Figure 1).
SiGLeC-7 AND iNFLAMMATiON iN Hiv-1 
iNFeCTiON
Since from the very beginning of HIV-1 pandemic, it became 
clear that the occurrence of a persistent inflammation is a 
hallmark of the disease together with the establishment of viral 
reservoirs (108, 109). Chronic inflammation also leads to a 
long-term activation of immune system even in the presence of 
ART and low levels of viremia (110). Several HIV-1-mediated 
mechanisms have been reported to induce an aberrant state of 
long-lasting inflammation, including the pathologic transloca-
tion of commensal micro-flora from the mucosal interfaces to 
both lamina propria and mesenteric lymph nodes in response 
to the massive depletion of mucosal CD4pos T occurring during 
the acute phases of the infection (111). Macrophages, other then 
constitutively expressing several members of the Siglec family, 
also represent the sentinels of the host innate immune system 
against pathogens at mucosal interface (5, 112). In the case of 
HIV-1 infection, the persistent engagement of inflammatory 
pathway in macrophages chronically challenged by the virus 
itself or by several opportunistic pathogens likely contributes 
to induce a chronic state of immune activation. Indeed, it has 
been reported that Siglec-7 on MDMs is able to bind different 
pathogens either expressing sialic acid residues (i.e., HIV-1, K1 
strain of Escherichia coli and Candida albicans) or not expressing 
syalilated glycans (i.e., K12 strain of E. coli and Zymosan yeast 
particles) (17, 52). Interestingly and in contrast with the reported 
inhibitory function of Siglec-7 in regulating the homeostasis and/
or the effector functions of T and NK cells (113–115), the engage-
ment of this type-I lectin on monocytes induces the production 
of several pro-inflammatory cytokines such as IL-6, IL-1α, CCL4, 
IL-8, and TNF-α (17). As a matter of fact, although coupled with 
ITIMs in its cytoplasmc domain, Siglec-7 promotes activation 
of monocytes via the engagement of an unconventional activat-
ing signal transduction pathway of these inhibitory motifs. It is 
well-known that ITIMs usually induce the phosphorylation of Src 
family kinases that, in turn, recruit phosphotyrosine phosphatase 
(PTP) such as Src homology region 2 domain-containing phos-
phatase-1 (SHP-1) and SHP-2. These PTPs switches off cellular 
pathways by dephosphorylating tyrosine residues and also pre-
vents the activation signals that originate from receptors coupled 
with ITAMs (116). Recently, the interpretation of this dichotomy 
in signal transduction has been revised due to the identification of 
new transmembrane receptors containing ITIMs. Indeed, several 
studies demonstrated that, in some circumstances and depending 
on the cellular context, ITIMs can propagate activation signals 
and ITAMs can mediate inhibition (117–124). One example is 
given by the dendritic-cell-associated C-type lectin 2, an ITIM 
bearing receptor, whose cross-linking with an anti-DCAL-2 
monoclonal Ab (mAb) recruits a SHP-2 domain that, instead of 
negatively regulating cell signaling, is involved in activating the 
ERK pathway and in inducing the production of IL-10, TNF-α, 
IL-6, and CCL5 (117). This phenomenon is also occurring with 
Siglec-7 isoform selectively expressed on monocyte and bearing 
“activating” ITIMs inducing the phosphorylation of ERK. This 
latter well-known signaling pathway triggers various transcrip-
tion factors modulating many genes involved in the immune 
activation (125). Therefore, the encounter of different pathogens 
by Siglec-7 expressed on monocytes and macrophages likely 
provide an additional mechanism contributing to the appearance 
of persistent inflammation during the course of HIV infection.
Besides inducing the production of pro-inflammatory cytokines 
and chemokines in monocytes and macrophages, the cross-
linking of Siglec-7 also induces an up-modulation of ICAM-1 and 
CD49e. These two adhesion molecules are known to play a rel-
evant role in the trans-endothelial migration of leukocytes during 
inflammatory responses following their binding with either the 
β2 integrin lymphocyte function-associated antigen (LFA-1) or 
macrophage 1 antigen expressed on endothelial cells. Moreover, 
the interaction between ICAM-1 and LFA-1 is able to deliver a 
co-stimulatory signal to T cells (126). Therefore, the engagement 
of Siglec-7 has also the potential to regulate the migration of 
other inflammatory cells toward tissue sites, where they deliver 
co-stimulatory signals. This is highly relevant at gut and cervix 
mucosal interfaces, as these two tissue sites highly enriched of 
macrophages represent the main gates of HIV-1 entrance (127, 
128). The activation and the migration of monocytes to tissues 
can lead to cellular activation and plastic polarization toward 
pro-inflammatory M1 or anti-inflammatory M2 macrophages on 
the basis of different signals and stimuli delivered within the local 
microenvironment (112). Further investigations are required to 
better understand the impact of HIV-1 binding to Siglecs con-
stitutively expressed on macrophages in the modulation of their 
plasticity toward a classic or alternative polarization, a process 
that is known to be highly affected and dysfunctional during 
the course of HIV-1 infection (85). This is highly relevant in the 
context of the synergic interplays by NK cells and macrophages 
aimed to induce and optimize the links between innate and adap-
tive immune responses. In particular, the NK  cell-macrophage 
cross talk occurring through mechanisms requiring both cell-
to-cell contacts and soluble mediators is key in the context of 
host–pathogen interactions (129–131) and during the course 
of viral infections (132). Indeed, it has been recently reported 
that M1 macrophages can prime the activation and the effector 
functions of NK cells that, in turn, are able to rescue M2 toward 
pro-inflammatory M1 polarization (133). This virtuous loop 
appears to be completed disrupted during the course of chronic 
and active HIV-1 infections that is characterized by a macrophage 
deactivation or M2 polarization and by the expansion of anergic 
CD56neg NK cells also impaired in the priming of autologous DCs 
(73, 75, 85). The cellular and molecular mechanisms behind the 
appearance of markedly dysfunctional NK cells and macrophages 
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are still unknown and not even the selective down-modulation 
of Siglec-7 on NK  cells has been clarified. Another important 
pathogenic element to elucidate is why the chronic HIV-1 replica-
tion induces the polarization of M2 macrophages that are also 
more susceptible to the infection through the engagement of 
several surface receptors including Siglec-7 (52, 90, 99). Finally, 
we do no know why HIV-1 binding to Siglec-7 does not induce 
a the polarization of macrophage toward M1 with a consequent 
priming of autologous NK cell able to better function as antiviral 
effectors. The elucidation of all these points will help us to better 
understand the basis of innate immune dysfunctions during the 
course of HIV-1 infection.
SiGLeCS AS POSSiBLe THeRAPeUTiC 
TARGeTS iN Hiv-1 iNFeCTiON
Targeting Siglecs as novel immunotherapy approaches has been 
proposed soon after the identification of Siglec-3 (CD33) and 
Siglec-2 (CD22) as biological markers of myeloid leukemias and 
B cell lymphomas, respectively (4). Indeed, the anti-Siglec-3 mAb 
Gemtuzumab ozogamicin is approved for treatment of acute mye-
loid leukemia, while Epratuzumab, the mAb targeting Siglec-2, is 
currently in clinical trials for treatment of acute lymphoblastic 
leukemia, follicular non-Hodgkins lymphoma, and autoimmune 
diseases (134–136). The identification of novel members within 
the Siglec family and the recent new insights disclosing the patho-
genic relevance of this type-I lectins in several model of human 
diseases shed new light for developing innovative therapeutic 
approaches targeting the immune-modulatory functions of these 
transmembrane receptors. In particular, the existence of peculiar 
functions exerted by several Siglecs in distinct immune cell 
populations make these lectin-type molecules suitable candidates 
for therapies modulating host–pathogen interactions and cellular 
signal transduction.
In the context of HIV-1 infection, other then using Siglec-1 
and Siglec-7 as possible clinical biomarkers, we can take advan-
tage of their ability of binding HIV-1 envelope and enhance/
induce the susceptibility to infections of both conventional 
and unconventional cell targets (52–55). Indeed, the use of 
pharmaceutical compounds or mAbs blocking the interac-
tions of HIV-1 with either Siglec-1 or Siglec-7 can potentially 
limit HIV-1 dissemination in several cellular compartments 
(i.e., monocytes/macrophages, DCs, and CD4pos T  cells). This 
approach is particularly relevant during acute infection in order 
to damp the ability of HIV-1 to infect immune cells, to slow down 
the CD4pos T cell depletion especially at mucosal interfaces and 
to put a break to the early establishment of immune activation 
and viral reservoirs. Furthermore, inhibiting HIV-1 uptake by 
Siglec-1 would also limit the infection of circulating monocytes 
that upregulate the surface expression of this type-I lectin in 
the acute phases of the infection (78, 79). Another possible 
therapeutic target is sSiglec-7 that is increased in the sera of AIDS 
patients and enhances the degree of infection of CD4pos T cells 
(52). The elucidation of the mechanism(s) inducing the down-
modulation of Siglec-7 on NK  cell surface and inducing the 
shedding of its soluble form in AIDS patients’ sera will certainly 
make it possible to develop strategies that will limit the ability 
of sSiglec-7 to spread the infection due to its capacity to carrier 
HIV-1 in periphery and enhance the susceptibility to infection of 
Siglec-7neg/CD4pos T cell targets.
In the context of developing a vaccine strategy, it has been also 
reported that Siglec-1 can be targeted to improve antigen presen-
tation to T cells on the basis of its effective and rapid endocytic 
activity following interaction with pathogens (137, 138). Further 
investigations are needed to assess whether such approach can 
be used for HIV-1. Finally, it is also possible to take advantage of 
the immune-modulatory potential of Siglecs by employing their 
natural ligands. In this regard, it has been recently reported that 
high-affinity synthetized glycans targeting Siglec-2 expressed on 
B cells compete in cis with the natural ligands and induce endocy-
tosis and killing of B cells (139). A similar approach could be used 
to inhibit the interactions between Siglecs and HIV-1. Particularly, 
attractive from a pharmaceutical perspective would be the use of 
lyposomal nanoparticles bearing Siglec glycan ligands (140).
CONCLUDiNG ReMARKS
Among the several mechanisms that HIV-1 has developed to 
evade host immune defenses there is the heavily conjugation 
on Gp120 of viral envelope with sialic acids residues that bind 
Siglec-1 and -7 mostly expressed on NK cells, macrophages, and 
DCs. These interactions are relevant for HIV-1 survival, serve as 
molecular mimicry for host immune responses, avoid immune 
attack, and facilitate viral entry. Indeed, the binding of HIV-1 to 
these type-I lectins induce and/or enhance the infections of target 
cells is associated with inflammatory pathways and correlated 
with disease progression (Figure 1). These novel insights disclos-
ing the key roles played by Siglecs in the pathogenesis of HIV-1 
infection open new avenues also for clinical perspectives. Indeed, 
this transmembrane type-I lectin could be either used as bio-
logical marker of disease or therapeutically targeted to limit viral 
dissemination and the establishment of viral reservoirs. Siglec-7 
and Siglec-1 dysfunctions in HIV-1 infection are also highly 
relevant to advance our knowledge in regard to the physiology 
and physiopathology of NK cells either alone or in the context 
of their interplays with both monocytes/macrophages and DCs.
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